| Literature DB >> 32855856 |
Jinhee Lee1,2, Takuya Iwasaki1,3,4, Shinichiro Ohtani1, Hidehito Matsui4, Ryohei Nejima1, Yosai Mori1, Fumie Kagaya1, Akiko Yagi1, Akiko Yoshimura3, Hideaki Hanaki4, Makoto Aihara2, Kazunori Miyata1.
Abstract
Purpose: We previously reported the presence of multidrug-resistant staphylococci on the ocular surface of glaucoma patients using prostaglandin analog drops for more than 1 year. Here, we investigated the effect of benzalkonium chloride (BAC) on these multidrug-resistant staphylococci.Entities:
Keywords: Staphylococcus epidermidis; benzalkonium chloride; multidrug resistance; prostaglandin analog; qacC/smr
Mesh:
Substances:
Year: 2020 PMID: 32855856 PMCID: PMC7422782 DOI: 10.1167/tvst.9.8.9
Source DB: PubMed Journal: Transl Vis Sci Technol ISSN: 2164-2591 Impact factor: 3.283
Eye Drops Used in This Study
| Xalatan (0.005%) | Travatan Z Ophthalmic Solution (0.004%) | |
|---|---|---|
| Main agent | Latanoprost | Travoprost |
| Preservative | Benzalkonium chloride | Boric acid, zinc chloride |
| Company | Pfizer, Inc. | Alcon Japan |
Minimum Inhibitory Concentration of Various Prostaglandin Eye Drops (Latanoprost, Travoprost, and BAC) Against S. epidermidis Isolates from the Ocular Surface of Glaucoma Patients
| MIC (µg/mL) | |||
|---|---|---|---|
| Isolates | Latanoprost | Travoprost | BAC, Mean ± SD |
| Isolates from Xa group | |||
| Total ( | >100 | >80 | 2.02 ± 1.86 |
| MSSE ( | >100 | >80 | 0.98 ± 2.89 |
| MRSE ( | >100 | >80 | 2.31 ± 1.55 |
| Isolates from Tz group | |||
| Total ( | >100 | >80 | 1.02 ± 1.57 |
| MSSE ( | >100 | >80 | 1.03 ± 1.62 |
| MRSE ( | >100 | >80 | 0.98 ± 1.55 |
MSSE, methicillin-sensitive S. epidermidis; MRSE, methicillin-resistant S. epidermidis.
Significant differences in total and MRSE isolates from Xa and Tz groups based on a t-test (P = 0.001).
Presence of qacA/B and qacC/smr Gene Sequences in S. epidermidis Isolates from Groups Using Different Eye Drops
| Gene Sequence | Isolates from Xa Group ( | Isolates from Tz Group ( |
|
|---|---|---|---|
|
| 1.00 | ||
| + | 7 | 4 | |
| – | 12 | 9 | |
|
| <0.001 | ||
| + | 15 | 2 | |
| – | 4 | 11 |
Statistical analysis using Fisher's exact test.
Presence of qacA/B and qacC/smr Gene Sequences in S. epidermidis Isolates with Respect to Methicillin Sensitivity
| Number of Isolates | |||
|---|---|---|---|
| Gene Sequence | Methicillin-Resistant | Methicillin-Sensitive |
|
|
| 1.00 | ||
| + | 7 | 4 | |
| – | 12 | 9 | |
|
| 0.01 | ||
| + | 14 | 3 | |
| – | 5 | 10 | |
Statistical analysis using Fisher's exact test.
Clonality of qacA/B Sequences of S. epidermidis Isolates Amplified by PCR
| Sequence | Change in Nucleotide and Amino Acid Residue | BLAST Search (100% Match): Plasmid Name (GenBank) | Clone No. |
|---|---|---|---|
| Type 1 | Prototype | pSK156 (61835) | 2 |
| Type 2 | c.542 G>C p.V181L, c.651 T>C p.F217S | pHOB1 (CP018843) | 3 |
| Type 3 | c.555 T>C p.V181L, c.651 T>C p.F217S | pKG-18 (AP019544.1) | 6 |
Figure.Correlation between the efflux pump genes detected by PCR methods and the MIC of BAC against S. epidermidis isolates. (A) The number of isolates positive (open bar) or negative (closed bar) for the qacA/B gene. (B) The number of isolates positive (open bar) or negative (closed bar) for the qacC/SMR gene. There was a significant correlation between the MIC of BAC and the detection of qacA/B and qacC/smr sequences (P = 0.03 and P < 0.001, respectively).
Correlation Between PCR Detection of qacA/B and qacC/smr Gene Sequences and Susceptibility Patterns of S. epidermidis Isolates
| PCR | MIC (µg/mL) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
| BAC | MPIPC | CAZ | IPM | MFLX | EM | VCM | LZD | |
| Xa Group | ||||||||||
| 1 | – | – | 0.39 | ≤0.25 | 2 | ≤0.063 | ≤0.063 | 0.25 | 1 | 1 |
| 2 | – | – | 0.78 | ≤0.25 | 2 | ≤0.063 | 0.125 | 0.25 | 1 | 1 |
| 3 | – | + | 0.78 | 2 | 8 | 0.125 | 1 | >128 | 2 | 1 |
| 4 | – | + | 1.56 | 1 | 8 | ≤0.063 | 2 | >128 | 2 | 1 |
| 5 | – | + | 1.56 | ≤0.25 | 1 | ≤0.063 | ≤0.063 | 4 | 1 | 1 |
| 6 | – | + | 1.56 | ≤0.25 | 4 | ≤0.063 | 0.125 | 64 | 2 | 2 |
| 7 | – | + | 1.56 | >8 | 16 | 0.5 | 64 | >128 | 2 | 1 |
| 8 | + | – | 1.56 | >8 | 32 | 0.5 | 1 | 0.25 | 2 | 1 |
| 9 | + | – | 3.13 | 4 | 16 | 0.5 | 1 | 0.25 | 1 | 1 |
| 10 | – | + | 3.13 | >8 | 16 | 1 | 32 | >128 | 2 | 1 |
| 11 | – | + | 3.13 | 4 | 8 | 0.125 | 0.125 | 64 | 2 | 1 |
| 12 | + | + | 3.13 | >8 | 32 | 4 | 1 | 32 | 2 | 1 |
| 13 | – | + | 3.13 | >8 | 32 | 4 | 1 | >128 | 2 | 1 |
| 14 | + | + | 3.13 | ≤0.25 | 2 | ≤0.063 | 1 | 32 | 2 | 0.5 |
| 15 | – | + | 3.13 | >8 | 32 | 1 | 2 | 0.5 | 2 | 1 |
| 16 | + | + | 3.13 | >8 | 32 | 2 | 1 | 64 | 2 | 1 |
| 17 | + | + | 3.13 | >8 | 32 | 1 | 2 | 64 | 2 | 1 |
| 18 | – | + | 3.13 | >8 | 32 | 2 | 1 | 0.25 | 2 | 1 |
| 19 | + | + | 3.13 | >8 | 16 | 0.25 | 1 | 64 | 2 | 1 |
| Total | 7 | 15 | ||||||||
| Tz Group | ||||||||||
| 20 | – | – | 0.39 | ≤0.25 | 4 | ≤0.063 | 0.125 | 0.25 | 2 | 0.5 |
| 21 | – | – | 0.78 | ≤0.25 | 4 | ≤0.063 | 0.125 | 0.25 | 2 | 1 |
| 22 | – | – | 0.78 | ≤0.25 | 4 | ≤0.063 | 0.25 | 0.25 | 1 | 1 |
| 23 | + | – | 0.78 | ≤0.25 | 2 | ≤0.063 | 0.125 | 0.25 | 2 | 1 |
| 24 | – | – | 0.78 | ≤0.25 | 2 | ≤0.063 | 0.125 | 0.25 | 2 | 1 |
| 25 | – | – | 0.78 | >8 | 16 | 0.125 | 0.125 | >128 | 2 | 1 |
| 26 | – | – | 0.78 | 2 | 8 | 0.125 | 0.125 | 16 | 2 | 1 |
| 27 | – | + | 1.56 | ≤0.25 | 4 | ≤0.063 | 0.125 | 0.25 | 2 | 1 |
| 28 | – | – | 1.56 | ≤0.25 | 4 | ≤0.063 | 0.125 | 0.25 | 2 | 2 |
| 29 | + | – | 1.56 | ≤0.25 | 8 | ≤0.063 | 1 | 32 | 2 | 1 |
| 30 | + | – | 1.56 | >8 | 32 | 0.5 | 2 | 0.25 | 2 | 1 |
| 31 | – | + | 1.56 | 2 | 8 | 0.125 | 1 | 0.25 | 1 | 1 |
| 32 | + | – | 1.56 | ≤0.25 | 4 | ≤0.063 | ≤0.063 | 32 | 2 | 1 |
| Total | 4 | 2 | ||||||||
Numbers with shaded background are determined to be resistant or intermediate according to the Clinical & Laboratory Standard Institute. MPIPC, methyl-phenyl-isoxazolyl penicillin; CAZ, ceftazidime; IPM, imipenem; MFLX, moxifloxacin; EM, erythromycin; VCM, vancomycin; LZD, linezolid.